MWG0 Stock Overview
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
InMed Pharmaceuticals Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.22 |
52 Week High | US$1.53 |
52 Week Low | US$0.19 |
Beta | 0.48 |
1 Month Change | -25.85% |
3 Month Change | -23.37% |
1 Year Change | -79.70% |
3 Year Change | -99.65% |
5 Year Change | -99.91% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
MWG0 | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 9.1% | 1.6% | -0.3% |
1Y | -79.7% | -26.4% | 2.8% |
Return vs Industry: MWG0 underperformed the German Pharmaceuticals industry which returned -26.4% over the past year.
Return vs Market: MWG0 underperformed the German Market which returned 2.8% over the past year.
Price Volatility
MWG0 volatility | |
---|---|
MWG0 Average Weekly Movement | 17.8% |
Pharmaceuticals Industry Average Movement | 7.1% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MWG0's share price has been volatile over the past 3 months.
Volatility Over Time: MWG0's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1981 | 13 | Eric Adams | www.inmedpharma.com |
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products.
InMed Pharmaceuticals Inc. Fundamentals Summary
MWG0 fundamental statistics | |
---|---|
Market cap | €1.44m |
Earnings (TTM) | -€5.90m |
Revenue (TTM) | €5.10m |
0.3x
P/S Ratio-0.3x
P/E RatioIs MWG0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MWG0 income statement (TTM) | |
---|---|
Revenue | US$5.49m |
Cost of Revenue | US$3.38m |
Gross Profit | US$2.11m |
Other Expenses | US$8.46m |
Earnings | -US$6.35m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.05 |
Gross Margin | 38.42% |
Net Profit Margin | -115.75% |
Debt/Equity Ratio | 0% |
How did MWG0 perform over the long term?
See historical performance and comparison